Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib with Concurrent Radiation for Newly Diagnosed Resectable Rectal Cancer

LESSONS LEARNED. Colorectal cancers exhibit a high level of cyclooxygenase‐2 (COX‐2) expression with strong preclinical rationale for improved clinical outcomes with COX‐2 inhibition. Celecoxib is a COX‐2 inhibitor and we have shown that it can be safely combined with capecitabine and oxaliplatin as...

Descripción completa

Detalles Bibliográficos
Autores principales: Araujo‐Mino, Emilio P., Patt, Yehuda Z., Murray‐Krezan, Cristina, Hanson, Joshua A., Bansal, Pranshu, Liem, Ben J., Rajput, Ashwani, Fekrazad, M. Houman, Heywood, Glenory, Lee, Fa Chyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5759821/
https://www.ncbi.nlm.nih.gov/pubmed/29158365
http://dx.doi.org/10.1634/theoncologist.2017-0474

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5759821/
https://www.ncbi.nlm.nih.gov/pubmed/29158365
http://dx.doi.org/10.1634/theoncologist.2017-0474

Ejemplares similares